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of regulating energy balance, such as so-called adaptiveIntroduction
thermogenesis. The latter, at least in rodents, involvesThe ability to assure continuous availability of energy
the function of brown adipose tissue (BAT; Lowell anddespite highly variable energy supplies in the environ-
Flier, 1996). Unlike white adipose tissue, which is de-ment is a major determinant of the survival of all species.
signed for energy storage, BAT is designed for the regu-For higher organisms including mammals, a solution to
lated expenditure of energy as heat. Neural signals thatthis problem involved development of the capacity to
emanate from the hypothalamus and are transmittedefficiently store excess energy as triglycerides in adi-
by the autonomic nervous system regulate this highlypose cells, from which stored energy could be rapidly
innervated tissue, which employs theuncoupling proteinreleased for use at other sites. In addition, physiological
(UCP), a 32 kDa protein of the inner mitochondrial mem-mechanisms arose to enhance survival by stabilizing
brane to uncouple mitochondrial respiration (Jezek etadipose energy stores during prolonged periods of defi-
al., 1994).cient or excess nutritional availability. The outlines of
Despite this highly regulated physiological system,such physiological systems are simple: with prolonged
it is evident that obesity is currently an exceptionallynutritional deprivation, falling energy stores are sensed,
common problem in humans, and the search for causalleading to increased food-seeking behavior and de-
factors has been intensifying. The last several yearscreased energy expenditure; with prolonged nutritional
have produced breakthroughs in two obesity-related ar-abundance, food intake is reduced and energy expendi-
eas of investigation: the identification of genetic lociture is increased to avoid excessive energy storage, i.e.
at which mutations cause obesity in rodents, and theobesity. The systems involved in such adaptations are
identification of transcription factors that regulate thereferred to as systems for regulated energy balance.
differentiation, pattern of gene expression, and lipidA physiological system for regulation of energy bal-
content of fat cells. This review is intended, first, toance and avoidance of obesity would be expected to
provide an up-to-date perspective on advances in thesehave several requirements. The first is a mechanism by
two areas. The second goal of this review will be towhich information on the level of energy stores in adi-
describe recent work that may begin to link these pre-pose tissue can be sensed, and the resulting information
viously distinct areas of investigation, that is, to explainrelayed to regulatory sites elsewhere in the body. Al-
how a disequilibrium in energy homeostasis caused bythough a number of candidate mechanisms have been
obesity genes may ultimately result in changes in fatdescribed for a feedback signaling system reflecting
cell number and lipid content.the amount of adipose energy stores (Schwartz et al.,
1994), the existence of such a mechanism was made
certain by the cloning of the ob gene and identification Obesity Genes
The identification of five genes responsible for distinctof its encoded protein leptin (Zhang et al., 1994; see
below). The second requirement is a mechanism where- syndromes of spontaneous monogenic obesity in mice
(Table 1) has advanced our knowledge dramatically, andby such a signal can be receivedand integrated at one or
more regulatory sites, most likely in the central nervous together with insights obtained through induced muta-
tions, a preliminary view of a “wiring diagram” for thesystem. The hypothalamus has been known to be a key
brain region for regulation of metabolism and energy control of body weight is beginning to take shape. The
pace of progress has been extremely rapid, and thisexpenditure, and a variety of chemical or physical le-
sions in this region can produce dramatic syndromes of discussion will therefore be selective.
The ob and db Geneshypo- or hyperphagia accompanied by severe metabolic
disturbance (Bray et al., 1990). Identification of the leptin The identification of the ob (Zhang et al., 1994) and db
(Tartaglia et al., 1995) genes over the past 18 monthsreceptor as the product of another obesity gene (db;
Tartaglia et al., 1995), and demonstration of its expres- has provided the first genetic framework on which future
understanding of body weight regulation and obesitysion in the hypothalamus (Chen et al., 1996; Lee et al.,
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Table 1. Monogenic Obesity Syndromes in Mice
Chromosome/ Gene Where Mode of Human Disease
Gene Inheritance Product Expressed Action Analog
ob 6/AR Leptin White adipose tissue Absent signal of No coding mutants
energy stores found; ?? linkages
in some groups
db 4/AR Leptin receptor Hypothalamus; choroid Absent reception No coding
plexus; elsewhere of above signal mutants found (n 5 5)
tub 7/AR Hypothalamic Hypothalamus ?? role in hypothalamic ???
protein signal pathway
Ay 2/AD Agouti Ubiquitously in mutants, ?? antagonize melanocortin ???
skin in normal mice signal in CNS or
other sites
fat 8/AR Carboxypeptidase E Endocrine/neuroendocrine ?? altered CNS ? 1 patient with similar
tissues neuropeptide, such as syndrome
MCH (O’Rahilly et al., 1995)
AD, autosomal dominant; AR, autosomal recessive.
can bebuilt. The products of the ob and db genes consti- 1995). It is likely that an unidentified intrinsic factor such
as an intracellular metabolite or another signal whosetute a hormone-receptor pair (leptin and the leptin re-
ceptor, respectively) that provides molecular identity to abundance is linked to adipose stores is the major deter-
minant of leptin expression. In addition, a number ofone system through which the status of energy stores
is signaled to the brain. Total inability to produce leptin factors that are extrinsic to the adipocyte can regulate
leptin expression both in vitro and in vivo, over a period(ob/ob) or respond to it (db/db) result in profound, early
onset obesity with persistently excessive food intake, of hours, in some cases changing leptin expression out
of proportion to changing fat stores. These include insu-inappropriately decreased energy expenditure, severe
insulin resistance, and genetic background–dependent lin (MacDougald et al., 1995a), glucocorticoids (Slieker
et al., 1996), beta adrenergic ligands (Mantzoros et al.,diabetes. Repletion of ob/ob mice with recombinant lep-
tin is remarkably effective at reversing all aspects of the 1996), and cytokines (Grunfeld et al., 1996). Although
the putative role of leptin as a long term integrativesyndrome so far studied over a period of days to weeks
(Halaas et al., 1995; Pellymounter et al., 1995; Campfield signal of energy stores suggested that leptin levels
would change slowly, it appears that short term changeset al., 1995; Chehab et al., 1996). Weight loss following
leptin treatment of ob/ob mice results from both reduc- in leptin levels may have important consequences as
well.tion in food intake and increased energy expenditure
(Schwartz et al., 1996; Halaas et al., 1995; Pellymounter The functional analysis of the leptin promoter is at an
early stage; functional C/EBP binding sites are presentet al., 1995). Energy expenditure is mediated by both
increased physical activity and activity-independent (He et al., 1995; Hwang et al., 1996). Thiazolidinediones
reduce leptin mRNA (Zhang et al., 1996), consistent withthermogenesis, which in part appears to involve activa-
tion of brown adipose tissue (Collins et al., 1996). Rever- involvement of PPARg on the leptin promoter (Kallen
and Lazar, 1996). Cloning and identification of the leptinsal of insulin resistance and diabetes in ob/ob mice by
leptin is in part a consequence of reduced food intake receptor DNA reveal it to be a member of the class I
cytokine receptor family that signals, at least in part,and body weight, but the rapid time course and dose
response for such effects suggests that additional ac- through the Jak/STAT pathway (Ghilardi et al., 1996).
The leptin receptor gene is complex, producing multipletions of leptin may be involved, acting either directly
through peripheral sites, or more likely, through the brain splice variants expressed at very low levels in a tissue
specific manner (Lee et al., 1996). The db allele encodes(Schwartz et al., 1996). Although administration of exog-
enous leptin can limit the obesity that occurs when cer- a mutation in the non-coding region that alters splicing
and results in deletion of most of the intracellular, signal-tain strains of normal mice are exposed to high fat diets
(diet-induced obesity) (Campfield et al., 1995), the doses ing domain (Chen et al., 1996; Lee et al., 1996). The
predominant site in which this “signaling” form of therequired are high compared to those that are effective
in ob/ob mice, and it is not yet established whether receptor is expressed appears to be the hypothalamus,
but the mRNA for this form is also seen at lower abun-physiological resistance of normal mice to obesity
caused by high fat feeding or other environmental stimuli dance elsewhere as detected by RT-PCR. Missense mu-
tation of the leptin receptor gene has also been de-is mediated by increased levels of endogenous leptin.
High levels of circulating leptin and what is now being scribed in the Zucker fa/fa rat (Phillips et al., 1996; Chua
et al., 1996). One or more short forms of the receptorreferred to as “leptin resistance” are found in the vast
majority of obese humans so far reported (Considine et that are unlikely to have signaling potential are heavily
expressed in several tissues including the choroidal., 1995; Maffei et al., 1995).
How Does This System Work? plexus, where the receptors may mediate uptake across
the blood–cerebral spinal fluid barrier. The possibilitiesIn the fed state, leptin is expressed and secreted by
adipocytes in proportion to their triglyceride stores, and of blood–brain barrier transport or direct access to sites
in the brain that reside outside the blood brain barriercirculates in the blood where its levels correlate to a
remarkable degree with the extent of obesity (e.g. Fred- have not been excluded. What appears to be a saturable
system for transport of leptin from blood to brain haserich et al., 1995a; Maffei et al., 1995; Considine et al.,
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been described in vivo in rats (Banks et al 1996), and in serotonin and norepinephrine, is in an embryonic stage
normal humans, levels of leptin in cerebral spinal fluid and will be an important subject for future research.
are approximately 2–5% of serum levels (Schwartz et Role of Leptin: Obesity vs Starvation?
al., 1996). Initial reports suggest that the ratio of cerebral The discovery of leptin and its receptor as genetic loci
spinal fluid to plasma leptin shows characteristics of carrying mutations that cause severe obesity in rodents
saturability when leptin levels in plasma rise to the level suggested to most observers that one physiological role
seen in obesity (Schwartz et al., 1996; Caro et al., 1996), of leptin is to prevent obesity during exposure to nutri-
and this could be one of the factors that might limit the tional excess (i.e. a negative feedback “adipostatic”
ability of peripheral leptin to effectively signal the state function). However, it is not clear that prevention of
of adiposity to the central nervous system. obesity is leptin’s most important role or the problem
Leptin Targets that the leptin system evolved to address. What other
Identifying targets for leptin action in thebrain is a matter role might leptin be playing? In addition to rising as
of great interest, both from scientific and pharmaceuti- energy stores increase, leptin levels were noted to fall
cal perspectives. One target for leptin action is the level with weight loss (Frederich et al., 1995; Maffei et al.,
of expression of the hypothalamic neuropeptide Y (NPY) 1995; Considine et al., 1995). Since an effective adapta-
(Dryden et al., 1994). This 36 amino acid peptide is ex- tion to starvation would offer a survival advantage under
pressed widely throughout the nervous system. Expres- the conditions of intermittent food supplies that is likely
sion of NPY mRNA in the arcuate nucleus of the hypo- to have confronted mammals through evolution, it is
thalamus is increased in ob/ob and db/db mice and in possible that leptin evolved to provide a signal to inform
response to fasting in normal rats (Marks et al., 1992). the brain that energy stores are sufficient, and, in paral-
Repetitive administration of NPY into the central nervous lel, to entrain the brain’s response to starvation. Recent
system produces hyperphagia and obesity (Stanley et experiments support this hypothesis (Ahimaet al., 1996).
al., 1986) decreased energy expenditure with suppres- Several changes in neuroendocrine status accompany
sion of BAT activity (Billington et al., 1991), and hyperin- fasting or limitation of food intake. These adaptations,
sulinemia (Zarjevski et al., 1993), all features of obesity which include limitation of reproductive competence,
in ob/ob and db/db mice. On the basis of its pattern of reduced thyroid hormone levels, and activation of the
nutritionally regulated expression in the arcuate nu- pituitary-adrenal “stress” axis are prevented or blunted
cleus, and the consequences of its direct administration
when leptin levels are replaced exogenously during a
into the brain, NPY has been proposed to be a key
fast (Ahima et al., 1996). The dose of leptin required for
effector of the hypothalamic regulation of nutritional ho-
these neuroendocrine actions is lower than the dose
meostasis; it’s overexpression may be an important link
required to produce weight loss in normal rodents. In
between leptin deficiency and the development of obe-
addition, except for ob/ob mice, which are very sensitive
sity. Since leptin treatment of ob/ob mice suppresses
to leptin, obesity in most rodent models (Frederich etNPY expression in the arcuate nucleus (Stephens et al.,
al., 1995, 1995a; Maffei et al., 1995) and in most human1995; Schwartz et al., 1996), and leptin may act directly
obesity (Considine et al., 1995) is associated with highon NPY-expressing cells in vitro (Stephens et al., 1995),
levels of leptin and what is being referred to as “leptinthe NPY neuron is likely to be a key leptin target. The
resistance.” It is not yet clear whether “leptin resistance”recent identification of a new species of NPY receptor
reflects widespread disease due to dysfunction in path-(Y5) that has characteristics expected of a receptor that
ways downstream of leptin, or the inherent physiologicmediates the action of NPY on food intake (Gerald et
limitations of the putative role of leptin as a signal toal., 1996) is a potentially important advance. However,
prevent obesity. This question will only be answered bythe precise role of NPY is made less clear by the pheno-
careful studies of leptin physiology in lean and obesetype of NPY knockout mice, which apparently regulate
animals and humans under a variety of nutritional condi-feeding and body weight normally, and respond to exog-
tions and genetic analysis of the pathways downstreamenous leptin with normal or even excessive inhibition of
of leptin in lean and obese individuals.food intake (Erickson et al., 1996). Whether absence of
Agouti, Fat, TubNPY will alter the phenotype of mice with various forms
Whereas identification of ob and db established a de-of obesity will presumably soon be known through phys-
fined physiological loop, the identity of the agouti, fatiological studies and genetic crosses. Whatever the re-
and tub mutations has yet to elucidate the physiologicalsults of such experiments, it already seems clear that
system that is perturbed by these mutant alleles to pro-suppression of arcuate NPY cannot be the sole mecha-
duce obesity. The obesity in these models developsnism for leptin action to regulate body weight, and one or
more slowly than is seen with ob or db, although in eachmore other central leptin targets must exist. One recent
case an action of the mutant gene product in the centralcandidate for an alternative leptin target is melanin con-
nervous system is suggested. Lethal yellow (Ay) is ancentrating hormone, a neuropeptide that is expressed
autosomal dominant syndrome of obesity with insulinpredominantly in the hypothalamus, is overexpressed
resistance, diabetes, and yellow coat color that is duein ob/ob and starved normal mice, and causes hyper-
to widespread ectopic expression of the agouti proteinphagia after injection into the lateral cerebral ventricles
(Bultman et al., 1992). This gene, which was the firstof rats (Qu et al., 1996). Neuropeptides that inhibit food
obesity locus to be cloned, encodes a 131 amino acidintake, such as corticotropin releasing hormone (Arase
protein that is normally expressed solely in skin duringet al., 1988) are also potential targets of leptin. Our un-
hair growth, where it influences hair pigmentation andderstanding of how these and other central neuropep-
coat color (Manne et al., 1995). It does this by antagoniz-tides interact, with each other and with classical neuro-
transmitters that regulate feeding behavior such as ing the binding of melanocyte stimulating hormone to
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one or more melanocortin receptors on the melanocyte mass index can be ascribed to genetic factors (Bouch-
ard, 1995). In rare cases, human obesity is the conse-(Lu et al., 1994). It has not yet been established at what
quence of single gene disorders (e.g., Bardet Biedl,tissue site or through what receptor mechanism ectopi-
Prader Willi, Ahlstrom, Cohen syndromes), and thesecally expressed agouti acts to cause obesity. It is intri-
syndromes are characterized as well by specific clinicalguing that melanin concentrating hormone and agouti
phenotypes that led to their identification. The responsi-share an ability to antagonize melanocyte stimulating
ble genes have been mapped, but not yet identified,hormone action in some systems (Rance and Baker,
and do not appear to be human equivalents of any of1979). This parallel suggests that agouti might cause
the identified mouse obesity genes.obesity by mimicking an action of melanin concentrating
In most human obesity, it is believed that a limitedhormone to antagonize melanocyte stimulating hor-
number of genes interact with the environment to pro-mone or a melanocyte stimulating hormone–like mole-
duce the final phenotype, and several strategies havecule at one or more sites in the brain.
been used to search for such genes. Candidate genesThe fat mutation produces an autosomal recessive
have been chosen for analysis based on the roles thatobesity with hyperinsulinemia that was assumed to be
their gene products are thought to play in the regulationcompensatory to insulin resistance, as in other obesity
of energy balance. In large studies of the ob gene (Con-models (Coleman and Eicher, 1990). It was found, how-
sidine et al., 1995; Maffei et al., 1996), and a limitedever, that these mice responded normally to exogenous
study of the ob receptor gene (Considine et al., 1996) ininsulin, and that much of the circulating insulin was an
obese humans, functionally significant mutations withinincompletely processed and biologically less active
the coding regions of these genes have not been found.form. The molecular explanation arrived when the fat
On the other hand, linkage between the ob gene hasmutation was mapped to the carboxypeptidase E gene,
been found in some (Clement et al., 1996; Reed et al.,with fat being a missense mutation that abolishes en-
1996) obese populations, and in an Hispanic population,zyme activity in extracts of pancreatic islets and pituitary
obesity has been linked to a region of thegenome (1p22-(Naggert et al., 1995). Precisely how obesity and accom-
p31) (Duggirala et al., 1996) to which the leptin receptorpanying infertility result from a defect in prohormone
also maps. Linkage of human obesity to human tub, fat,processing is as yet unknown, but speculation has cen-
or agouti genes has not yet been reported. Three othertered on the possibility that defects in processing of
candidate genes for which linkages of as yet uncertainhypothalmic neuropeptides may be the answer. This
significance have been reported are worthy of note.idea is supported by a recent report that processing of
These include the beta 3 adrenergic receptor (Widen ethypothalamic neuropeptides is abnormal in fat/fat mice,
al.,1995), which could be linked to functional impairmentwith one unexpected result being increased level of the
in lipolysis in white adipocytes or thermogenesis in BAT;aforementioned neuropeptide melanin concentrating
the glucocorticoid receptor (Clement et al., 1996a),hormone (Rovere et al., 1996). A potential human homo-
which could influence obesity through the known abilitylog of this disorder has recently been described in an
of glucocorticoids to act permissively at a number ofobese patient with high levels of incompletely processed
key steps in energy balance; and the Na1,K1 ATPaseinsulin and proopiomelanocortin (O’Rahilly et al., 1995),
(Deriaz et al., 1994), whose function in maintenance ofbut whether the genetic basis for this disorder involves
ion gradients contributes importantly to energy expen-carboxypeptidase E or another prohormone processing
diture.enzyme, such as prohormone convertase 1 (PC1), has
not yet been established.
The most recent obesity gene to be identified is tub, Control of Adipose Cell Size and Number
another autosomal recessive obesity of later onset, in When the intake of energy chronically exceeds energy
which retinal degeneration and neurosensory hearing expenditure, most of the excess energy is stored in
loss are found (Coleman and Eicher, 1990). The tub gene the form of triglycerides in adipose tissue. Increased
was identified through positional cloning and encodes adipose tissue masscan arise through an increase in cell
a novel and highly conserved 505 amino acid protein size, cell number, or both. Adipose cells are remarkably
that is suggested to be cytosolic in location (Noben- variable in size, reflecting principally the amount of
Trauth et al., 1996; Kleyn et al., 1996). It is most highly stored triglyceride. Mild obesity mainly reflects an in-
expressed in eye, testis, and brain, where location in creased adipose cell size (hypertrophic obesity) while
hypothalamic nuclei important for regulation of body more severe obesity or obesity arising in childhood typi-
weight is consistent with tub playing a role somewhere cally also involves an increased fat cell number (hyper-
in the pathway for neural regulation of energy balance. plastic obesity). As a key part of a homeostatic system
Another approach to identification of genes involved controlling energy balance, the molecular mechanisms
in the obesity phenotype has involved quantitative trait that regulate preadipose cell growth, adipose differenti-
locus mapping, using intercrosses between strains of ation, and lipogenesis in fat cells have been subject to
rodents with high or low susceptibility to diet induced extensive scrutiny. Recent years have seen an explosive
obesity. Some of the identified loci appear to map close increase in our understanding of the transcriptional ba-
to one or more of the identified mouse obesity genes sis of fat cell differentiation and adipose cell gene ex-
(e.g., West et al., 1995). pression, particularly the identification of transcription
Genetic Basis for Human Obesity factors that can promote adipogenesis in a dominant
Studies in twins, adoptees, and families suggest that fashion. Central to our understanding here are PPARg,
the C/EBPs and ADD1/SREBP1.from 40% to as much as 80% of the variance in body
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PPARg is a member of the PPAR (peroxisome prolifer- that PPARa can induce some adipogenesis when stimu-
lated by its strongest activators, while PPARd could notator activated receptor) subfamily of nuclear hormone
receptors. PPARg exists as two isoforms (g1 and g2) stimulate detectable fat cell formation (Brun et al., 1996).
Since many fibroblastic cells express a low but detect-formed by alternative splicing (Zhu et al., 1995) and dif-
fering in their N-termini (Tontonoz et al., 1994a). PPARg2 able level of PPARg, it seems likely that the previous
suggestions of an adipogenic response through PPARd,is expressed at high levels in adipose tissue, while low
levels of PPARg1 can be found in many other tissues. especially when stimulated with high levels of non-
selective PPAR activators, were actually due to the acti-This receptor is induced very early in adipose cell differ-
entiation, and is present at higher levels in preadipo- vation of PPARg. While PPARa stimulated differentiation
was less extensive and slower than that stimulated bycytes than other fibroblastic cells. PPARg appears to
function as both a direct regulator of many fat-specific PPARg, the same basic program of gene expression
was observed. Hence, the possibility exists that PPARagenes and also as a “master” regulator that can trigger
the entire program of adipogenesis. PPARg forms a het- may contribute to the adipogenesis of some depots, in
normal or pathological states. As specific high affinityerodimer with RXRa and has been shown to bind directly
to well characterized fat-specific enhancers from the ligands become available for all of the PPARs, a much
more critical analysis of their function will be possible.adipocyte P2 (aP2; Tontonoz et al., 1994a) and phospho-
enolpyruvate carboxykinase (PEPCK) genes (Tontonoz The C/EBPs and a Transcriptional Pathway
for Adipogenesiset al., 1994b). In fact, PPARg was cloned as a component
of a transcription factor, ARF6, that bound to the aP2 PPARg is not the only transcription factor that is signifi-
cantly elevated in adipocyte differentiation. C/EBPa, b,enhancer (Tontonoz et al., 1994a), and it was cloned
independently through homology screens seeking new d, and ADD-1 (also called SREBP-1) are all markedly
induced during differentiation in culture, although theymembers of the PPAR family (e.g., Zhu et al., 1993). As
a member of the nuclear receptor family, the ability of are not expressed in an adipose-selective fashion in
vivo. C/EBPa is increased relatively late in the processPPARg to increase transcription through its DNA recog-
nition site (DR-1, direct repeat, 1 base spacer) depends of adipogenesis but ectopic expression of high levels
of this factoralone can induce thedifferentiation of manyon the binding of ligands. Earlier work with PPARs relied
on “activators” that presumably functioned by stimulat- fibroblastic cell lines (Freytag et al., 1994). On the other
hand, when expressed at or near the mRNA levels seening the intracellular production of ligands. These activa-
tors include drugs that caused peroxisome proliferation in mature fat cells, this factor has only a modest adipo-
genic action in fibroblasts (Tontonoz et al., 1994c). Pre-(hence the name PPAR) such as clofibrate, ETYA,
Wy14,643, as well as a variety of other fatty acid deriva- cocious expression of C/EBPa can accelerate the en-
dogenous differentiation program of preadipocytes,tives (e.g., Green and Wahli, 1994). Most recently, the
first direct ligands for PPARg have been described in- while antisense mRNA blocks the differentiation mark-
edly (reviewed by MacDougald and Lane, 1995). Thecluding 15-deoxyD12,14 prostaglandin J2 (15dPGJ) and
the thiazolidinediones, an exciting new class of insulin- important role of C/EBPa in adipose development is
clearly shown in a knockout mouse. This genetic disrup-sensitizing drugs in clinical development for non-insulin
dependent diabetes mellitus (discussed below). tion causes a major reduction in the lipid content of the
fat tissue; however, fat cell differentiation apparentlyThe regulatory role that PPARg can play in adipogen-
esis is vividly illustrated through ectopic expression of still occurs (Wang et al., 1995). C/EBPa, like PPARg,
directly binds to many fat cell–specific genes (MacDou-this receptor. When expressed with viral vectors at or
below the levels normally seen in fat cells, fibroblasts gald and Lane, 1995). Unlike PPARg, which tends to
bind to distal enhancer regions, C/EBP tends to bind atare efficiently converted into bona fide adipocytes upon
application of PPARg activators or ligands (Tontonoz et sites clustered in proximal promoter regions.
A dramatically cooperative or synergistic relationshipal., 1994c). In fact, using pioglitazone, a thiazolidinedi-
one ligand, greater than 95% of these cells can be differ- between PPARg and C/EBPa is observed when both of
these factors are expressed in the same cells. Underentiated to fat (Brun et al., 1996). This adipogenic re-
sponse is apparently through the transcriptional activity conditions lacking a PPARg activator, where neither
factor alone promoted significant adipogenesis inof PPARg, since a point mutation in one of the zinc
fingers required for DNA binding completely ablated this fibroblasts, coexpression gave abundant differentiation
(Tontonoz et al., 1994c). This cooperation is even moreaction (Tontonoz et al., 1994c). The adipogenic activity
of PPARg, like the well established 3T3-L1 and 3T3- obvious when a cell with little adipogenic potential, such
as a determined myoblast, is challenged with these fac-F442A preadipocyte cell lines, is markedly enhanced by
the presence of insulin (Hu et al., 1995). tors. Neither C/EBPa or PPARg (with activator) alone
could give rise to fat differentiation from G8 myoblasts,Since all of the PPARs (a, d, and g) can bind to the
same DNA sequences, and all are expressed in at least but coexpression caused the differentiation of at least
70% of these cells into adipocytes (Hu et al., 1995).some fat depots, it is interesting to know whether a and
d (also called NUC-1 or FAAR) play any role in adipogen- Thus, while either PPARg and C/EBPa can promote adi-
pogenesis under very favorable experimental condi-esis. Unlike PPARg, PPARa or d are not expressed pref-
erentially in fat, but there have been suggestions that tions, such as in a very susceptible precursor cell or with
the application of high levels of adipogenic hormones orboth of these receptors could play a direct or indirect
role in adipogenesis (Yu et al., 1995; Teboul et al., 1995). PPARg ligands, it is likely that these factors cooperate
in many, if not most physiological circumstances.Most recently, in a direct comparison of the adipogenic
potential of PPARs expressed in 3T3 cells, it was shown A very interesting role for C/EBPb in adipogenesis
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has recently emerged from the labs of McKnight and adipogenesis and fatty acid metabolism while the other
is primarily a cholesterol regulatory protein. It is notableFarmer. Ectopic expression of this factor also promotes
adipogenesis in fibroblasts (Yeh et al., 1995). Of the that ADD1/SREBP1 is regulated dramatically in fat cell
differentiation and has been shown to function positivelytwo major forms of the C/EBPb protein, liver-enriched
activating protein (LAP) hasmuch more activity than liver in adipogenesis (Kim and Spiegelman, 1996), but is not
observed to be activated through proteolytic cleavageenriched inhibitory protein (LIP). Notably, expression of
C/EBPb, which is normally induced very early in adipo- upon cholesterol depletion of hamster liver (Zheng et al.,
1995). In contrast, SREBP2 is proteolytically activatedgenesis, increases the expression of PPARg (Wu et al.,
1995). The differentiation of cells expressing C/EBPb upon development of a cholesterol-depleted state, and
hence may play the more important role in cholesterolectopically is dependent on the addition of a PPAR acti-
vator, suggesting that an important role of C/EBPb in homeostasis in vivo (Zheng et al., 1995). The relative
roles of these two proteins is being critically analyzedadipogenesis may be to turn on PPARg expression.
C/EBPd has also been implicated in the regulation of in several cellular and genetic systems.
The outlines of a regulatory loop involving the keyPPARg; coexpression of both C/EBPb and d is neces-
sary to fully induce PPARg to levels seen in adipocytes adipogenic factors during differentiation can now be
envisioned (Figure 1). C/EBPb and g are elevated quite(Wu et al., 1996). The promoter for PPARg2, the isoform
expressed most selectively in fat, contains two C/EBP early in this process, probably in response to certain
hormones, and may function directly to increase thebinding sites (Zhu et al., 1995), suggesting a direct regu-
latory circuit. expression of PPARg. If the extracellular and intracellu-
lar conditions provide the necessary adipogenic hor-Another factor that appears to interact directly or indi-
rectly with PPARg is ADD1/SREBP1. This protein was mones and PPARg ligands, the transcriptional activity
of this molecule will begin the cascade of genes thatcloned independently as a basic helix-loop-helix (bHLH)
protein induced very early in adipogenesis (Tontonoz et constitute the process of adipogenesis. ADD1/SREBP1
promotes this process by augmenting the transcrip-al., 1993), and a sterol response element (SRE) binding
protein (Yokoyama et al., 1993). This factor is quite un- tional ability of PPARg. Since PPARg activation results
in the expression of most or all of the program of differ-usual in that it has dual specificity in DNA binding, inter-
acting with certain E-box sequences and the SRE. Dual entiation, including C/EBPa, it is reasonable to imagine
that PPARg–C/EBPa cooperation brings about maximalspecificity is controlled by a single tyrosine residue in
the basic DNA binding region, at a site where all other differentiation and a full program of lipogenesis. The
ability of PPARg and C/EBPs to engage in cross-regula-bHLH factors have an arginine (Kimet al., 1995). SREBP1
and its close homolog SREBP2 are posttranscriptionally tion may be sufficient to maintain the differentiated
state, once it has been initiated. Of course, maintainingactivated by proteolytic cleavage of a large, transmem-
brane form of the protein (Wang et al., 1994). When this regulatory loop will require the generation of an
endogenous PPARg ligand. The ability of ADD1/SREBP1expressed ectopically in fibroblasts ADD1/SREBP1 has
two notable activities. Under culture conditions not con- to regulate both key genes of fatty acid metabolism and
augment PPARg activity suggests that this transcriptionducive to adipogenesis, it induces two key genes of fatty
acid metabolism, fatty acid synthetase and lipoprotein factor may be important in the process of ligand gener-
ation.lipase, without stimulating visible fat cell formation (Kim
and Spiegelman, 1996). Under conditions strongly fa- Several major unanswered questions remain in this
scheme. If C/EBPb is a major inducer of PPARg in vivo,voring adipogenesis, ADD1/SREBP1 can increase the
percentage of fibroblasts that undergo differentiation why is PPARg not expressed abundantly in other tissues
that express high levels of C/EBPb, such as liver? Thisfrom 2–3% to 15–20%. This effect is probably due, at
least in part, to an influence of PPARg activity, since suggests the involvement of other important regulators,
positive or negative, in fat and non-adipose tissues. Acotransfection with ADD1 causes a 3–4 fold increase in
the activity of PPARg through its DNA binding site but second question relates to the quantitative regulation
of C/EBPa in fat. Although expression and activation ofhas no influence on the activity of C/EBPa through its
DNA recognition sequence (Kim and Spiegelman, 1996). PPARg in fibroblasts is sufficient to give some expres-
sion of C/EBPa, it is much lower than the expression inIn parallel with these studies, the lab of Brown and
Goldstein has implicated ADD1/SREBP1 and SREBP2 normal adipose tissue, again arguing for the involvement
of as yetundescribed molecules. It will also be importantin the control of several key genes of cholesterol homeo-
stasis (Yokoyama et al., 1993). This suggests that this to understand the mechanisms of cooperation between
PPARg and C/EBPa in differentiation. How this coopera-family of factors could coordinate the regulation of two
of the major lipid pathways, those leading to fatty acids tion occurs at a molecular level is not clear. Since many
fat cell–specific genes have binding sites for both pro-and cholesterol. Since the construction of very low den-
sity lipoproteins (VLDL), the parents molecule of IDL and teins, a highly synergistic interaction with the core tran-
scriptional machinery is the simplest explanation. TheLDL, contains both lipids, it is likely that the dual action
of the ADD1/SREBP family reflects the need to coordi- specificity of the PPARg–C/EBPa relationship is indi-
cated by the fact that other PPARs do not synergizenate these two separate but related metabolic path-
ways. In this regard, it will be interesting toknow whether with C/EBPa in adipogenesis. It is also possible that
C/EBPa activates genes whose products control endog-the two different pathways in which these transcription
factors participate segregate along the lines of E-box enous PPARg ligand formation. Finally, a direct protein–
protein interaction that increases the activity of one orversus SRE binding. Also interesting is the possibility
that one of these two isoforms is primarily involved in both of these factors has not been ruled out.
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Figure 1. Cascade of Transcription Factors
Involved in Adipocyte Differentiation
Hormonal signals initiate a transient increase
in expression of C/EBPb and C/EBPd. These
factors stimulate the expression of PPARg.
ADD1/SREBP1, in addition to regulating
genes important in fatty acid metabolism, in-
creases the activity of PPARg, possibly
through the generation of ligand. Activation
of PPARg by ligand allows the differentiation
process to proceed. Subsequently, C/EBPa
expression is induced. C/EBPa may allow for
the continued expression of PPARg once the
levels of C/EBPb and C/EBPd have de-
creased. It is likely that both C/EBPa and
PPARg are important for maintaining the fully
differentiated state.
One crucial question that has not yet yielded to current The better-studied prostaglandin hormones are
known to act via cell surface receptors. However, theinvestigation is the transcriptional control of white ver-
notion that these lipids can permeate cell membranessus brown adipose differentiation. As described above,
and enter the nucleus is feasible. It is not yet knownwhite fat cells and brown adipose cells play opposite
whether 15-dPGJ2 is generated in cells undergoing adi-roles in energy homeostasis although they express a
pogenesis at levels that would suggest that it couldvery similar pattern of genes. Since the key component
function as a true endogenous ligand for PPARg.of energy dissipation employed by brown adipose cells
Thiazolidinediones (TZDs) are an exciting new classis UCP, it seems likely that a hint about the key differenti-
of synthetic drugs that increase sensitivity to insulin ination factors might come from the study of this gene.
patients that are resistant to this hormone. Since insulinRecent data suggests that this promoter, like many
resistance is a ubiquitous correlate of obesity and agenes expressed in white adipocytes, has regulatory
major component of the form of diabetes (non-insulinsites for the C/EBPs and PPARg (Yubero et al., 1994;
dependent diabetes mellitus, NIDDM)commonly associ-Sears et al., 1996), both of which are expressed in BAT
ated with obesity, these drugs may have great medicaland WAT. Hence, it is likely that other transcription fac-
importance. Currently, one member of this class, trogli-tors or modified versions of these factors must contrib-
tazone, has reported successful results in a phase IIIute to the critical divergence in the determination of
clinical trial to treat NIDDM (Nolan et al., 1994). Thethese two cell types.
connection between the thiazolidinediones and PPARgPPARg Ligands: Natural and Synthetic
was first prompted by the studies of Rolf Kletzien andThe nuclear receptors are built to receive chemical sig-
colleagues. Theyshowed that pioglitazone could specif-nals that trigger their activity. Since at least one activity
ically induce the aP2 gene in differentiating adipocytes,of PPARg, to promote adipogenesis, is both very dra-
and this drug appeared to function through the pre-matic and of considerable physiological importance,
viously identified differentiation control element, ARE6,
there has been an immediate surge of activity to identify
in the aP2 enhancer (Harris and Kletzien, 1994). After
ligands, both natural and synthetic.
the ARE6 binding factor (ARF6) was cloned and shown
The identification of a natural ligand for PPARg was to be PPARg (Tontonoz et al., 1994a), Ibrahimi et al.
preceded by research showing that many polyunsatu- (1994) found that TZDs could activate PPARs, though
rated fatty acids and eicosonoid derivatives, such as they did not examine PPARg. In fact, the anti-diabetic
ETYA and Wy14,643, were activators of the PPARs TZDs BRL49653 and pioglitazone elicit a strong activa-
(Green and Wahli, 1994). Using transcriptional activation tion of PPARg, with relatively little activity on PPARa
through a reporter gene as an assay, it was found that and d (Lehmann et al., 1995; Forman et al., 1995). Using
the prostaglandin D arm of this family had high activity 3H-BRL49653, this drug was shown to bind directly to
(Forman et al., 1995; Kliewer et al., 1995). 15-dPGJ2 was PPARg, while binding to the other PPARs was not de-
potent and gave a rapid response, consistent with a tectable. The rank order of potency of the TZDs closely
direct interaction with this receptor. Indeed, two groups matches the anti-diabetic action, suggesting that PPARg
found that this prostaglandin could bind directly to is the functional receptor in this action (Willson et al.,
PPARg, as evidenced by competition for binding with a 1996). As expected for an agonistic ligand, these com-
synthetic thiazolidinedione ligand (see below), with a Ki pounds have very powerfully adipogenic action in cells
of z2 mM. As expected for a direct agonist, it is very ectopically expressing PPARg, or in fibroblastic cells
effectiveat promoting adipogenesis when addedto cells that express low but significant amounts of this recep-
tor. It is worth noting that TZDs had been reported tothat express PPARg.
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stimulate the differentiation of preadipocyte cell lines Finally, it should be appreciated that these models
well before the identification of PPARg as a target (Klet- are not mutually exclusive. It is entirely possible that all
zien et al., 1992). of these mechanisms contribute and the quantitative
PPARg and Insulin Resistance importance of each can only be ascertained through a
The activity of TZDs to promote adipogenesis in culture combination of genetic studies, especially tissue-spe-
and improve insulin sensitivity in vivo may seem para- cific knock-outs of PPARg, and studies of whole body
doxical in that increased adipogenesis is most com- physiology.
monly associated with obesity, a condition tightly linked
to insulin resistance. However, this paradox becomes Linking Ingestive Behavior to Adipogenesis
less troubling when one remembers that obesity is fun- Given the rash of recent insights into obesity genes and
damentally a disorder of energy balance, with theexcess adipocyte biology, the task remains to integrate these
energy stored in fat. Indeed, adipose differentiation itself often disparate new findings, first with each other, and
is associated with thedevelopment of a marked increase then with knowledge of classical metabolism, endocri-
in insulin sensitivity, correlating with greater expression nology and nutrition, to create a more complete under-
of the insulin receptor, IRS-1, GLUT-4 and probably standing of the biology of weight regulation and obesity.
many other genes that are fundamental to the metabolic Although we are still a long way from such a synthesis,
response to insulin. Excessive adipocyte number is only the outlines of some new connections can now be seen.
contributory to insulin resistance when it is linked (as it One need not be a rocket scientist to notice that in-
usually is in vivo) with an excessive burden of stored creased food intake tends to be associated with obesity,
energy. but it is less obvious by what mechanisms increased
One can imagine several plausible mechanisms for ingested nutrients are transformed into more and bigger
TZD-improved insulin sensitivity. It is likely that one or fat cells. Following the ingestion, digestion, and absorp-
more key genes relating to insulin action are capable tion of nutrients, levels of substrates rise, and these,
of being modulated by an increased activity of PPARg along with signals emanating from the gut, produce
activity, even in fully differentiated fat. A TZD ligand, changing levels of hormones that guide the substrates
given at pharmacological doses, would be expected to to their sites of storage. Insulin is the preeminent hor-
control such genes and improve the insulin sensitivity mone of the fed state: elevated levels prevent excessive
of this tissue. Of course, a major question is how can
rises in blood glucose by promoting glucose storage
TZDs improve insulin sensitivity of muscle and liver,
and use and decreasing glucose production by the liver.
other tissues that are important targets of insulin. One
Insulin also has a critical role in lipid metabolism, pro-
possibility is that TZDs function in a similar manner de-
moting thestorage of triglycerides in adipocytes through
scribed above through the low levels of PPARg that are
numerous actions on this cell. Among these are stimula-
expressed in many non-adipose tissues. Alternatively,
tion of glucose uptake and inhibition of lipolysis, whichadipose tissue PPARg might be the primary target of
occur very rapidly through glucose transporter proteinTZDs but this might result in the generation of signals
(GLUT 4) translocation or covalent modification of hor-from fat that affect insulin sensitivity in muscle and liver.
mone sensitive lipase, respectively. Insulin also stimu-Simply by virtue of improving insulin sensitivity in fat, the
lates fatty acid and triglyceride synthesis, through therate of fatty acid release would be expected todecrease,
induction of key lipogenic enzymes such as fatty acidsince the suppression of lipolysis is a major action of
synthetase and glycerophosphate dehydrogenase, andinsulin. In addition, fatty acids have been shown to be
induction of lipoprotein lipase. To this picture of insulincapable of inducing insulin resistance (Svedberg et al.,
action, we can now add recent insights into adipogenic1991). There may also be protein products of fat that
transcription factors. It is clear that an insulin signalaffect systemic insulin sensitivity and are regulated by
promotes the adipogenic action of PPARg, since differ-TZDs. One example of this is known: tumor necrosis
entiation of cells expressing this molecule is greatly in-factor a (TNFa). As mentioned above, TNFa produced
creased by this hormone (Hu et al., 1995). The naturein fat has been implicated in systemic insulin resistance,
of this signal isnot yet characterized. Although an insulinespecially in obesity (reviewed by Hotamisligil et al.,
stimulated change in PPAR phosphorylation and func-1996). TZDs have been shown to affect 2 arms of the
tion may be predicted based on observations with otherTNF pathway: it reduces TNFa expression in fat tissue
members of the steroid receptor superfamily (Bunonein vivo (Hofmannet al., 1994) and itcan also blockcertain
et al., 1996), it has also been observed that the abun-actions of TNFa on preadipose and adipose cell cultures
dance of PPARg isoforms in fat falls with starvation and(Szalkowski et al., 1995). Whether TZD can specifically
insulin deficiency diabetes (Vidal-Puig et al., 1996). Thisinterfere with the action of TNFa to inhibit signaling
could occur through regulation of C/EBPb and d, whichthrough the tyrosine kinase activity of the insulin recep-
have themselves been shown to be transiently inducedtor has not yet been investigated. A further contributing
by insulin in cell culture (MacDougald et al., 1995b).fact to improved insulin sensitivity might be if TZDs do
Thus, the actions of insulin to transduce the nutritionaltrigger more, smaller cells. It has been suggested that
state of the organism to molecular machinery linked tosmaller fat cells tend to have greater insulin sensitivity
production of new fat cells may involve changes in boththan large, more lipid-laden cells (Abbott and Foley,
the levels and functional state of PPARg as well as1987). A redistribution of lipid into more cells could in-
C/EBPb and d. Another positive link between adipogen-crease insulin sensitivity, but since the adipose mass is
esis and insulin involves ADD1/SREBP1. This molecule,a less significant sink for glucose disposed than muscle,
which promotes adipogenesis and fatty acid metabo-it is not clear how large an increase in insulin sensitivity
this could generate. lism, has been shown to be influenced by the presence
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Figure 2. A Homeostatic Cycle for the Con-
trol of Energy Balance
The white adipocyte produces leptin as a
function of adipose energy stores. Leptin acts
through receptors in the hypothalamus to
regulate appetite, BAT activity and insulin se-
cretion via sympathetic nervous system
(SNS) output, and neuroendocrine function,
including reproduction. Ingested nutrients
stimulate insulin secretion, and together
these may act through several transcription
factors to promote adipose differentiation
and lipogenesis. Adipocytes secrete proteins
in addition to leptin which may have the ca-
pacity to act locally and/or systemically to
influence energy balance.
of insulin. While ADD1/SREBP1 activity has been shown in both preadipose cells and mature adipocytes is an
important area for future study.to be increased by insulin, it is not yet clear whether
this occurs by protein modification or at some other
level (Streicher et al., 1996). Taken together, it appears Energy Balance: Elements of a Homeostatic Cycle
It is now clear that the systems that influence food intakethat the response to feeding, at least in part via insulin,
promotes both energy storage in fat and the adipogenic and adiposity can be viewed as a cycle, as shown in
Figure 2. As discussed above, the key elements areprogram itself through PPARg and perhaps ADD1/
SREBP1. Paradoxically, C/EBPa levels have been dem- likely to be the fat-produced hormone leptin, the neural
system for integration of signals related to energy bal-onstrated to be negatively regulated by insulin. While
this effect cannot explain the positive role of insulin in ance, the pancreatic production of the hormone insulin
and the effects of this hormone and eicosonoids onadipogenesis, it may contribute to the downregulation
observed in certain fat cell genes, such as GLUT4, in adipogenic transcription factors, particularly PPARg.
However, it would be extremely naive to think that theseresponse to insulin (MacDougald et al., 1995b).
Glucocorticoids also represent a potentially important are the only important players in the fat–brain homeo-
static system. Indeed, several other novel proteins se-link between obesity genes and adipogenesis. Many of
the monogenic obesity syndromes in rodents develop creted by fat that enter the circulation have been de-
scribed, though their function is not yet known. Thesea hyperglucocorticoid state and reversal of this state
with adrenalectomy profoundly reduces obesity and include adipsin (Flier et al., 1987), angiotensinogen
(Frederich et al., 1992), plasminogen activator inhibitor Iseveral linked metabolic disorders. It has recently been
shown that the induction of PPARg by C/EBPb and d (PAI I; Samad and Loskutoff, 1996), and ACRP30/adipoQ
(Hu et al., 1995; Scherer et al., 1995). It is highly likely thatdepends almost entirely on the presence of a glucocorti-
coid (Wu et al., 1996). This induction of PPARg does not other fat derived molecules with interesting systemic
functions will be described. Similarly, the wiring diagramrequire ongoing protein synthesis, and hence, is likely to
represent a direct action of the liganded glucocorticoid of neural signaling molecules is very much at an explor-
atory stage. Although many neuropeptides are knownreceptor on the PPARg promoter.
Another potentially direct link between diet and adipo- to affect food intake, their relative importance in various
nutritional states and the manner in which these neuro-genesis involves the natural ligands for PPARg. Many
PPARg activators and the only identified biological li- transmitters and neuromodulators interact must be de-
termined.gand (15-dPGJ2) are eicosanoid derivatives. All eicosa-
noids are derived from arachidonic or other essential It is fair to ask what implications arise from this new
concept of a homeostatic cycle, in terms of our under-polyunsaturated fatty acids that must be supplied
through the diet. It is not clear whether these PPARg standing of normal physiology and disease, as well as
our ability to intervene therapeutically. First, the multipleligands or ligand precursors enter adipose cell precur-
sors directly from the bloodstream or are first stored in levels of feedback control help to explain how most
individuals maintain a rather impressive control of bodya membrane lipid compartment. The mechanisms lead-
ing to ligand import or generation of PPARg ligands weight. In order to maintain a weight change of less
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than 10 Kg over a 10 year period, an adult of 70 Kg Ultimately,our increased appreciation for thecomplex
and cyclical nature of energy balance controls suggestsmust maintain greater than a 98% congruence between
energy expenditure and energy intake. Surely this must caution if not modesty as our reductionist approaches,
so useful in generating specific molecular targets, aredepend on multiple levels of feedback control involving
signals between the regulatory centers in the hypothala- applied to the in vivo settings. It is possible that unex-
pected problems will develop as we test new drugsmus and adipose mass, food intake, and energy expen-
diture. Secondly, one might predict that experimental to control food intake, increase energy expenditure, or
directly manipulate fat cell development. However,perturbations in various parts of this system would
cause unexpected or even paradoxical results. Indeed, these very same interrelationships among complex
physiological systems may allow for compensation andit was considered an intriguing mystery for years how
monogenic mutations such as ob and db could cause allow new “set points” to be achieved without disastrous
complications. An example of this could be the develop-both increased food intake and decreased thermogene-
sis. This was only explained when the absence of leptin ment of antagonists to PPARg as a treatment for obesity
through the direct inhibition of fat cell formation. Evenwas shown tocause bothof these effects. More recently,
mice with a reduction in brown fat through expression if we assume that such molecules will be developed, and
that they effectively decrease fat cell number withoutof a tissue-specific toxigene were found to develop obe-
sity, with the expected decrease in thermogenesis (Low- adversely affecting insulin sensitivity, the continuation
of energy intake at the same rate that induced obesityell et al., 1993). Completely unexpected, however, was
the increase in food intake that these mice exhibit. Since would require that this energy be stored as lipid in other
tissues, such as liver or muscle, or remain in the bloodleptin levels are very high rather than deficient in these
mice (Frederich et al., 1995), this argues strongly for as stream. These are all very problematic outcomes. Only
if reduced fat cell number causes a compensatory de-yet undiscovered regulatory pathways from brown fat
to the brain. Along similar lines, beta 3–selective adren- crease in food intake or increase in energy expenditure
could such an approach be useful. Fortunately, such aergic agonists, developed as anti-obesity drugs that
would stimulate these fat-selective receptors and in- scenario is now conceivable. A reduction in adipose cell
number would presumably lead to an increase in thecrease b-oxidation of fatty acids and energy expenditure
acutely reduce food intake and stimulate insulin secre- size of those cells and hence, increased leptin synthesis.
Furthermore, blockage of PPARg itself might have ation in mice (Susulic et al., 1995) through as yet unknown
mechanisms that are independent of leptin (Mantzoros similar effect at the level of the leptin promoter. If in-
creased leptin in this context caused reduced food in-et al., 1996).
The cyclical nature of energy homeostatic mecha- take and increased energy expenditure, a beneficial cy-
cle and development of a new, lower set-point might benisms also suggest that significant disorders of energy
balance could result from primary lesions at sites in achieved. Of course, this scenario is highly speculative
but illustrates the complications and opportunities thatthese pathways that arenot necessarilydirectly involved
in controlling food intake. This could explain the ex- this new knowledge now affords.
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